|
Originally published In Press as doi:10.1074/jbc.M204665200 on May 24, 2002
J. Biol. Chem., Vol. 277, Issue 33, 29953-29962, August 16, 2002
Isolation and Functional Analysis of Mouse UbA52 Gene and Its
Relevance to Diabetic Nephropathy*
Lin
Sun ,
Xiaomin
Pan ,
Jun
Wada§,
Christian S.
Haas ,
Rudolf P.
Wuthrich ,
Farhad R.
Danesh¶,
Sumant S.
Chugh¶, and
Yashpal S.
Kanwar ¶
From the Departments of Pathology and
¶ Medicine, Northwestern University Medical School, Chicago,
Illinois 60611 and the § Department of Medicine, Okayama
University, Okayama 700-8558, Japan
Received for publication, May 13, 2002
 |
ABSTRACT |
In delineating the mechanism(s) of diabetic
nephropathy various novel genes have been isolated, whereas others
remain to be discovered. We identified several up-regulated genes in
the kidneys of diabetic newborn mice. Among them was UbA52, a ubiquitin
ribosomal fusion protein. Its mRNA expression in the kidney was
proportional to blood glucose levels. By in situ
hybridization and immunohistochemistry, UbA52 was exclusively localized
to renal tubules, and its expression was markedly increased in diabetic
mice. The up-regulated UbA52 mRNA and protein expression were also
observed in Madin-Darby canine kidney cells, a tubular cell
line, treated with 30 mM glucose in both cell lysates and
ribosomal fractions. To explore the mechanism(s) of its increased
expression, UbA52 genomic DNA was isolated. A transcription start site
at 22 bp from the initiation codon was identified and confirmed by
primer extension analysis. The UbA52 promoter region included glucose
response-related E-box sequences and stress response elements (STRE).
Unlike in humans, mouse UbA52 gene had no introns in the coding or
5'-ATG-flanking regions. To identify the DNA segment with maximal
promoter activity, deletion constructs were prepared using a pSEAP
vector system and transfected into COS7 kidney cells. Maximal activity
was confined to 198 to +68 bp, which included E-boxes and STRE
motifs. A dose-dependent increase in the promoter activity
was observed in cells exposed to high glucose. Mutations in the first
E-box (CAGCTG TGGCTG) or STRE
(CCCCT CATCT) resulted in a decrease in the
SEAP activity under high glucose ambience. Given the presence of
glucose-responsive motifs in the promoter region and decrease in the
SEAP activity in E-box mutants in the presence of glucose, these data
suggest that UbA52, a ribosomal fusion protein, may be relevant in the pathogenesis of diabetic nephropathy.
 |
INTRODUCTION |
Diabetic nephropathy is the most common cause of end stage renal
disease in the United States. It is characterized by thickening of
basement membranes and mesangial expansion with progression into
glomerulosclerosis, tubular atrophy, and interstitial fibrosis, ultimately resulting in renal failure (1). A wide variety of mechanisms
in the pathogenesis of diabetic nephropathy have been proposed. They
include accumulation of nonenzymatic glycated end products in the
kidney, oxidation of renal glycoproteins by reactive oxygen species,
intracellular accumulation of sorbitol generated by the reduction of
glucose by aldose reductase, activation of protein kinase
C-diacylglycerol pathway, involvement of mitogen-activated protein kinase and growth factors, e.g. insulin-like
growth factor and transforming growth factor- , and alterations in
renal hemodynamics (2-7). Involvement of such diverse mechanisms would
indicate that a vast number of molecules and different signal
transduction pathways are involved in its pathogenesis. In this regard,
newer molecules exhibiting a transcriptional response to hyperglycemia are being discovered at a rapid pace during the last decade, and their
identification has given new insights in the pathogenesis of diabetic
nephropathy. The identification of these molecules has been facilitated
by the use of various molecular biology techniques that employ the
isolation of differentially expressed genes in the hyperglycemic
versus the normoglycemic state. Such techniques include gene
discovery array, representational difference analysis of cDNA,
traditional subtractive or differential hybridization, and differential
display (8). The use of these techniques has led to the successful
isolation of several known human and mouse genes as well as the unknown
genes available in the expressed sequence tag mouse or human
NCBI data base. Most of these methods are not well suited for the
identification of rare messages because they require large amounts of
mRNA. Moreover, if the amount of mRNA is limited, it would
require several rounds of amplification and hybridization, resulting in
false positive signals. More recently, subtraction suppression
hybridization-PCR (SSH-PCR)1
(CLONTECH), a procedure based on the selective
amplification of differentially expressed genes in response to a given
experimental stimulus, has become available, and it equalizes for the
relative abundance of cDNAs within a target population and
minimizes the false identification of irrelevant genes.
Utilizing SSH-PCR procedure, nine differentially expressed genes from
the kidneys of newborn diabetic mice were isolated. Among them was
UbA52, a ubiquitin fusion protein. UbA52, a 128-amino acid fusion
protein, is made up of a 52-amino acid 60 S ribosomal protein attached
to a 76-amino acid ubiquitin peptide (9). The ubiquitin is highly
conserved in various species and is generated in cells by proteolysis
of larger proteins containing either polyubiquitin chains or ubiquitin
fused to carboxyl extension proteins. In humans, two ubiquitin-carboxyl
extension protein genes, UbA80 and UbA52, code for ubiquitin fused to
ribosomal proteins S27a and L40, respectively (9). The relevance of
ubiquitin in muscle wasting in diabetes is known, and activation of
ubiquitin-proteosome system has been well described in the literature
(10). However, the relevance of ubiquitin or the ubiquitin fusion
protein UbA52 in diabetic nephropathy remains to be investigated. This
paper describes the isolation of mouse UbA52 gene, its expression in
the kidneys of diabetic mice, and characterization of some of the
molecular features of its promoter region that may be relevant in the
pathogenesis of diabetic nephropathy.
 |
MATERIALS AND METHODS |
Animals and Induction of Diabetes--
A hyperglycemic state was
induced in pregnant female ICR mice (Harlan Co.) on day 13 of
gestation by injection of streptozotocin (200 mg/kg body weight;
Sigma). At day 16, blood glucose levels were measured, and mice with
blood glucose >250 mg/dl were selected for continuation of their
pregnancy. Following birth, blood glucose levels and body weights of
newborn mice of diabetic and nondiabetic mothers were determined, and
their kidneys were harvested.
Suppression Subtractive Hybridization-PCR--
Total RNA was
extracted from newborn kidneys of mouse by the acid guanidinium
isothiocyanate-phenol-chloroform extraction method as described
previously (11), and poly(A+) mRNA was isolated by
employing a Oligotex mRNA kit (Qiagen Co.). First strand and second
strand cDNA synthesis, RsaI endonuclease enzyme
digestion, adapter ligation, hybridization, and PCR amplification were
preformed as described in the PCR-select cDNA subtraction manual (CLONTECH; Ref. 11). The differential PCR
products in "tester" cDNA population subtracted from the
"driver" were cloned into pCR II vector, sequenced, and subjected
to a homology search by using BLAST program
(www.ncbi.nlm.nih.gov/BLAST/).
Northern Blot Analyses--
Total RNA was isolated from kidneys
of diabetic and control newborn mice and was subjected to 1.5% agarose
gel electrophoresis containing 2.2 M formaldehyde and
capillary-transferred onto Hybond N+ nylon membranes
(Amersham Biosciences). The prehybridization and hybridization were
performed with various [32P]dCTP-labeled (1 × 106 cpm/ml) partial length cDNA fragments derived from
SSH-PCR (11). In addition, the total RNA was isolated from kidneys of
newborn diabetic mice with different glucose levels in a range from 125 mg/dl to 450 mg/dl, and UbA52 mRNA expression was evaluated by Northern blot using mouse UbA52 cDNA probe.
Isolation of the Fusion Protein and Characterization of the
Antibody--
By Northern blot analyses several up-regulated genes
were identified. Among these, some as Rap1b, renal-specific
oxido-reductase and Tim44 have been previously investigated with
respect to diabetic pathobiology (11-13), whereas for others,
e.g. UbA52, limited information is available in the
literature. Thus, the relevance of UbA52 to diabetic nephropathy was
investigated in the present study. Initially, full-length mouse UbA52
cDNA was generated by rapid amplification of cDNA ends-PCR and
cloned into PCR II cloning vector (Invitrogen) and designated PCR
II/UbA52cDNA. Two expression constructs were generated by PCR using
PCR II/UbA52cDNA as template. First, the NdeI (CATATG)
and BamHI (GGATCC) sites were introduced using sense (5'-GGG
GGG CAT ATG ATC ATG CAG ATC TTC GTG AAG A-3') and antisense (5'-GGG GGG
GGA TCC TTT GAC CTT CTT CTT GGG GC-3') primers. The PCR products were
cloned into PCR II vector and then subcloned into NdeI- and
BamHI-digested pET15b plasmid vector (Novagen Co.). The
expression constructs, designated pET15b/UbA52, were sequenced. Transformation was performed using bacterial host BL21(DE3) (Novagen Co.). Two individual colonies were picked for generation of fusion protein. The purity of the isolated protein was assessed by SDS-PAGE analysis. Polyclonal antibodies were raised in rabbits, and
IgG-enriched fractions were prepared by ammonium sulfate precipitation.
Specificity of the antibody was determined by Western blot analysis.
The preparation of plasmids, fusion proteins, and antibodies and
Western blot analysis are detailed in previous publications
(11-14).
Tissue Expression Studies--
For localization of UbA52 in the
kidney, in situ hybridization and immunofluorescence studies
were performed as described previously (12). For in situ
hybridization, 3-µm-thick sections of paraffin-embedded kidney
tissues of newborn old diabetic and nondiabetic control mice were
prepared. They were deparaffinized, hydrated, and treated with
proteinase K. This was followed by prehybridization and hybridization
with 35[S]UTP-labeled UbA52 antisense riboprobes, which
were generated with a Riboprobe in Vitro Transcription
SystemTM (Promega). the tissue slides were coated with NTB2
photographic emulsion (Kodak), and the autoradiograms were prepared
after 3 weeks of exposure. The control included tissues hybridized with sense riboprobes. For immunofluorescence microscopy, 4-µm-thick cryostat sections were prepared from kidneys of 3-week-old mice as
well. The tissue sections were incubated with rabbit polyclonal anti-UbA52 antibody followed by a second incubation with fluorescein isothiocyanate-conjugated goat anti-rabbit IgG antibody. The sections were then examined with a UV microscope.
Effect of High Glucose on UbA52 Expression in Madin-Darby Canine
Kidney Cells--
Madin-Darby canine kidney (MDCK) cells (ATCC), a
well differentiated renal tubular epithelial cell line, was used for
further studies, and expression of UbA52 was examined in high glucose ambience. The MDCK cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Hyclone Labs), 100 units/ml penicillin, 100 units/ml streptomycin (Invitrogen) in an atmosphere of 5% CO2 and 95% air at 37 °C. At
the cell confluency of 70-80%, the concentration of fetal bovine
serum was reduced to 0.5%. The concentration of D-glucose
in the medium was adjusted to 5-30 mM, and the cultures
were maintained for 24 h. L-Glucose (30 mM) was used as control. The cells were then collected and processed for UbA52 mRNA and protein expression studies.
For mRNA expression studies, competitive RT-PCR was utilized.
First, a UbA52 competitive PCR template was constructed by using sense
(5'-AGA TCT TCG TGA AGA CCC TGA CGA CGA CAT GGA GAA GAT CTG G-3') and
antisense primers (5'-GGA AGG GGA CTT TAT TTG GTG AGG ATG CGG CAG TGG
CCA T-3'). These primers included UbA52 and -actin sequences. Using
these primers and a "mini gene construct" prepared previously (14)
(GenBankTM accession number U17140) as the target DNA, a
PCR product was generated, which was cloned into plasmid pCR II vector
and designated the competitive PCR template. Using this competitive mutant plasmid DNA, the expected sizes of the PCR products for UbA52
and -actin were 317 and 274 bp, respectively. Whereas in wild type
cDNA, the expected respective sizes of the PCR products were 434 and 430 bp. For quantitative competitive PCR, aliquots of first strand
cDNA, synthesized from RNA of MDCK cells treated with various
concentrations of glucose, were mixed with serial dilutions of
competitive DNA and co-amplified in the presence of either -actin-
or UbA52-specific primer in a PCR mixture as described previously (14).
The PCR products were analyzed by 1.5% agarose gel electrophoreses.
For protein expression studies, immunoprecipitation procedures and
Western blot analyses were employed, as detailed previously (11, 12).
Briefly, the protein expression was determined in the whole cell lysate
as well as in the ribosomal fractions. The MDCK cells treated with
various concentrations of D-glucose were lysed with
radioimmune precipitation buffer. The insoluble material was removed by
centrifugation at 10,000 × g, and the protein
concentration in the supernatant was determined by Bradford assay and
adjusted to 1 mg/ml. About 500 µl of the supernatant was mixed with
polyclonal anti-UbA52 with gentle agitation at 4 °C for 2 h,
followed by the addition of 40 µl of 50% protein A-Sepharose 4B
(Amersham Biosciences), and incubation was extended for another 1 h at 4 °C. The protein A-Sepharose beads were then washed with
radioimmune precipitation buffer. About 30 µl of 2× SDS sample
buffer was added to the washed beads, boiled for 5 min, and subjected
to 12.5% SDS-PAGE. The gel proteins were transferred onto Nylon
membranes, which were then incubated with rabbit anti-UbA52 polyclonal
antibody followed by a second incubation with anti-rabbit IgG
conjugated with horseradish peroxidase, and then autoradiograms were
prepared by using the ECL detection system (Amersham Biosciences)
Because UbA52 is a protein that is fused with 60 S ribosome, its
expression in the ribrosomal fraction was assessed in MDCK cells
treated with various concentrations of D-glucose. The
ribosomes were prepared following the method of Sherton and Wool (15). The ribosomal proteins were extracted from the ribosomes and subjected to immunoprecipitation procedures and Western blot analyses as described above.
Cloning of Mouse UbA52 Genomic DNA--
Mouse genomic UbA52DNA
was isolated and cloned in two steps. First, 5'-flanking region of the
mouse UbA52 gene was isolated using the mouse GenomeWalker kit
(CLONTECH) following the vendor's instructions.
Utilizing gene-specific antisense primer Ub-G1(AS) (5'-ATG GTG TCA CTG
GGC TCG ACC TCA AGA GT-3'), a nested primer UbG1N(AS) (5'-GAT GGT CTT
GCC CGT CAG GGT CTT-3'), and the PvuII DNA library of the
kit, a PCR product of ~1 kb was generated, sequenced, cloned into pCR
II vector, and designated pCRII/UbA52cDNA. This PCR product
included the 5'-flanking region upstream of the open reading frame and
the initiation ATG codon. In the second step, PCRs were carried out to
isolate the remaining 3' end of the UbA52 gene. Using the mouse
genomic 129 SvJ DNA (Jackson Laboratories), Ub-C(SE) sense
(5'-CAG ACG CCA ACA TGC AGA TCT TCG TG-3'), and Ub-C(AS) antisense
(5'-ACC ACA GCT TTA TTT GAC CTT CTT CTT GG-3') primers, a PCR
product of ~0.4 kb was generated, which represented the 3' end of the
~1.4-kb UbA52 gene. The PCR product was cloned, sequenced, and
analyzed for various motifs using the NCBI web site
(www.motif.genome.ad.jp/MOTIF.html).
Primer Extension Analysis--
To determine the transcription
start site(s) of the mouse UbA52, a primer extension reaction was
carried out. The total RNA was extracted from mouse kidney, and after
determining its integrity, mRNA was isolated (11). An antisense
primer (UB-G1N (AS), 5'-GAT GGT CTT GCC CGT CAG GGT CTT-3'), the
sequence of which was derived from downstream of the 5' end of open
reading frame of UbA52, was synthesized. The primer (10 mol/µl)
was labeled with [ -32P]dATP (3,000 Ci/mmol; Amersham
Biosciences) and purified by ethanol precipitation. After annealing the
radiolabeled primer (~10,000 dpm) with mRNA (0.5 µg) at
58 °C for 20 min, the extension reaction was carried out at 42 °C
for 30 min using 1 unit of avian myeloblastosis virus-reverse
transcriptase (Promega) in a reaction buffer containing 2 mM dNTP and dithiothreitol in a total volume of 20 µl.
The reaction products were separated by 8% PAGE under denaturing
conditions, and autoradiograms were prepared. Various primer extension
reaction products were eluted from the gel, purified, cloned into pCR
II vector, and then sequenced.
UbA52 Gene Promoter Analyses--
To identify the minimal
promoter region and to understand the mechanism of glucose-induced
up-regulation of UbA52, a GreatEscApeTM SEAP system
(CLONTECH) and various deletion constructs were
employed. For generation of deletion constructs, first, five sense
Ub-G1(SE) (5'-GGG CTC GAG TCG ACG GCC CGG GCT GGT-3'),
Ub-G2(SE) (5'-GGG CTC GAG ATG CAA CTA GAG ACA CAA GCT
C-3'), Ub-G3(SE) (5'-GGG CTC GAG TGT ATT TGC CAG GCA CTG
GC-3'), Ub-G4(SE) (5'-GGG CTC GAG GCC TGG ATA GAG TCA TCT
G-3'), and Ub-G5(SE) (5'-GGG CTC GAG TTG AGC CTT GAT CAG
AAC CT-3') and an antisense Ub-G1(AS) (5'-5'-GGG AAG CTT ATG GTG TCA CTG GGC TCG ACC TCA AGA GT-3') primers were synthesized. XhoI (CTC GAG) and HindIII (AAG CTT) sites were
included in the sense and antisense primers, respectively. These sites
are underlined in the various primer sequences. Using these primers and
pCR II/UbA52gDNA (see above), various PCR products were generated and
cloned into XhoI- and HindIII-digested
pSEAP2-Enhancer plasmid vector (CLONTECH) and
sequenced. COS7 cells (a cell line derived from African monkey kidney;
ATCC) were transfected with various plasmid deletion constructs using
LipofectAMINETM 2000 reagent, and the minimal promoter
activity of the UbA52 gene was measured using a
GreatEscAPeTM SEAP fluorescence detection kit
(CLONTECH) in the supernatant of the cell cultures.
The activities of various deletion constructs were expressed as the
percentages of the activity in the deletion construct with the highest
promoter activity, which was designated as being 100%.
Mutation Analysis and Dose-dependent Effect of
Glucose on Promoter Activity--
The promoter analysis (see above)
indicated that the highest activity was confined to deletion construct
5 (DC5 198, +68 bp to 198 bp). Thus, this construct was
used to assess the dose-dependent effect of glucose (5-30
mM) on the promoter activity and for the mutational
analysis experiments. The SEAP activity of culture supernatants was
determined as described above. Next, promoter activity was assessed
after creating mutations in the motifs that are relevant to the glucose
regulation. The two motifs that were present in the mouse UbA52
promoter and may be involved in the glucose regulation included E-box
(CAGCTG, 129 bp to 134 bp) and putative stress response element
(STRE; CCCCT, 154 bp to 158 bp). Three mutant plasmids were
constructed by using a QuikChange site-directed mutagenesis kit
(Stratagene). For E-box MUT1, the CAGCTG motif
was changed to CAGTTG; for E-box MUT2, CAGCTG was changed to
TGGCTG; and for STRE,
CCCCT was changed to
CATCT. After confirming the sequence of mutant
plasmids, they were then transfected into COS7 cells as described
above, and the promoter activity was determined in cells exposed to
either 5 or 15 mM glucose for 48 h.
 |
RESULTS |
Isolation and Characterization of Differentially Expressed Genes in
Streptozotocin-induced Diabetic Mouse Newborn Kidney--
The
respective glucose levels of diabetic newborn versus control
mice were: 421 ± 29 versus 121 ± 12 mg/dl
(n = 50), respectively. Their respective body weights
were: 0.58 ± 0.05 versus 1.3 ± 0.07 grams. The
SSH-PCR followed by Northern blot analyses revealed nine different
cDNA fragments with up-regulated gene expression to varying degrees
in the hyperglycemic state (Fig. 1).
Nucleotide sequence analysis of cDNAs indicated that all of them
are known genes as follows: UbA52 (clone 1), heat shock protein 70 (clone 2), lactate dehydrogenase (clone 3), Rap1b (clone 4), nuclear ribonucleoprotein (clone 5), ferritin L subunit (clone 6), Na,K-ATPase (clone 7), renal specific oxido-reductase (clone 8), and inner mitochondrial membrane (Tim44) (clone 9). Among all these genes, the
up-regulation in the mRNA expression of nuclear ribonucleoprotein (clone 5) was only minimal in the hyperglycemic state. Because SSH-PCR
analysis revealed that UbA52 is up-regulated in hyperglycemic state,
considerations were given to study the mechanisms involved in the
up-regulation of UbA52 by glucose.

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 1.
Northern blot analyses of differentially
expressed genes in kidneys of normal and diabetic mice. Nine
cDNA fragments were isolated by SSH-PCR and used as hybridization
probes for Northern blot analysis of RNAs isolated from normal
(N) and diabetic (D) newborn mice. Column
1, ubiquitin, Ub/60S (transcript sizes, ~2.8, ~1.7,
and ~0.7 kb); column 2, heat shock protein 70, Hsp (transcript size, ~2.7 kb); column 3,
lactate dehydrogenase, LDH (transcript size, ~1.7 kb);
column 4, Rap1b (transcript size, ~2.3 kb); column
5, nuclear ribonucleoprotein, Nu-Rb (transcript size,
~1.4 kb); column 6, ferritin-L subunit,
Ferritin (transcript size, ~1.2 kb); column 7,
Na,K-ATPase, ATPase (transcript size, ~4.0 kb);
column 8, renal-specific oxido-reductase, RSOR
(transcript size, ~1.5 kb); column 9, inner mitochondrial
membrane, Tim44 (transcript size, ~2.0 kb); column
10, -actin (transcript size, ~2.2 kb, control).
|
|
Relationship of UbA52 mRNA Expression with
Hyperglycemia--
To investigate a possible relationship between the
degree of hyperglycemia and renal UbA52 mRNA expression, Northern
blot analyses were performed on the kidneys of newborn mice with
different blood glucose levels. Four transcripts of ~0.7, ~1.7,
~2.8, and ~4.5 kb were detected under basal conditions,
i.e. mice with a blood glucose level of 125 mg/dl. Their
sizes corresponded to known sizes of transcripts of UbA52 (0.7 kb),
ubiquitin B (1.7 kb), and ubiquitin C (4.5 and 2.8 kb) genes (Fig.
2A, lane 1). Their
expression increased proportionally to the blood glucose levels (Fig.
2A, lanes 2-4) and a ~5-fold increase in
expression in diabetic mice with a blood glucose levels of 450 mg/dl,
suggesting a relationship between hyperglycemia and renal ubiquitin
expression in the diabetic mice kidneys. No change in the -actin
expression was observed (Fig. 2C).

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 2.
Relationship between renal UbA52 mRNA
expression and blood glucose levels. Northern blot analysis of
kidneys from newborn mice with a blood glucose of 125 mg/dl (lane
1) shows four different sized transcripts representing UbA52 (0.7 kb), ubiquitin B (1.7 kb), and ubiquitin C (4.5 and 2.8 kb). In
diabetic mice, renal ubiquitin mRNA expression increases
proportionally to the blood glucose levels (A, lanes
2-4). The kidneys of mice with a blood glucose level of 450 mg/dl
(lane 4) have a more than 5-fold UbA52 mRNA expression
compared with those with a blood glucose of 125 mg/dl. mRNA
expression of -actin is unaffected by the blood glucose levels
(C). B depicts the quality and equal loading of
total RNA in various lanes as indicated by the 28 and 18 S bands.
|
|
Characterization of Its Recombinant Protein and Kidney
Expression--
A high level of protein expression was observed in
Escherichia coli BL21(DE3) cells that were transfected with
pET15b/UbA52 plasmid when induced with 1 mM of
isopropyl-1-thio- -D-galactopyranoside. Multiple bands
were observed in total cell lysate subjected to SDS-PAGE, and a
prominent band of ~17 kDa was observed as well (Fig.
3A, CLONE.1 and
CLONE.2). This band was not visualized when vector alone was
used for transformation (Fig. 3A, VECTOR).
Following the purification of proteins in the lysate by nickel column
chromatography, a single band of ~17 kDa was observed (Fig.
3B, CLONE.1 and CLONE.2). The excess
~2 kDa of mass is presumably derived from the His6 tag.
The fusion protein was used for generation of a rabbit polyclonal antibody, and its authenticity was confirmed by Western blot analysis. A major band of ~17 kDa was observed for the recombinant protein generated from two different cDNA clones (Fig. 3C,
CLONE.1 and CLONE.2), suggesting that the
antibody is specific for the UbA52 fusion protein.

View larger version (72K):
[in this window]
[in a new window]
|
Fig. 3.
SDS-PAGE analysis of recombinant
N-His6-UbA52 fusion protein. Several bands are present
in the lysates of two different cDNA clones (A,
CLONE.1 and CLONE.2) after
isopropyl-1-thio- -D-galactopyranoside induction. In
addition, a ~17-kDa prominent band is seen in the E. coli
cell lysates. Purification of cell lysates by nickel affinity
chromatography revealed a single major band of ~17 kDa (B,
CLONE.1 and CLONE.2). The Western blot analysis
confirmed the identity of the recombinant proteins of these two clones
to be the UbA52 fusion protein (C).
|
|
Tissue Expression of UbA52 in Kidneys of Streptozotocin-induced
Diabetic Mice--
In vivo expression of UbA52 in the
kidney of diabetic mice was evaluated by in situ
hybridization and immunohistochemistry. Although the kidneys of
nondiabetic control animals showed a restricted hybridization signal to
mid-cortical renal tubules (Fig. 4,
A and B), UbA52 mRNA expression in diabetic
newborn mice kidneys increased notably and was seen throughout the
cortex (Fig. 4, E and F). Immunofluorescence
studies revealed a parallel increase of UbA52 protein expression in the
renal tubules of diabetic mice (Fig. 4, G and H)
compared with control (Fig. 4, C and D). The UbA52 expression was not observed in glomeruli and medullary
tubules.

View larger version (118K):
[in this window]
[in a new window]
|
Fig. 4.
mRNA and protein expression of UbA52 in
kidneys of diabetic mice. In situ hybridization studies
reveal UbA52 mRNA expression in the cortical tubules of newborn
normoglycemic mice (A and B), and the mRNA
expression is notably increased in diabetic mice (E and
F). Immunofluorescence microscopy reveals UbA52
protein expression in renal tubules in the mid cortex (C and
D). A parallel notable increase in the UbA52 expression is
observed throughout the cortex in diabetic mice (G and
H). No expression is observed in the renal glomeruli and
medullary tubules.
|
|
UbA52 Expression in MDCK under High Glucose Stimulation--
To
assess whether the high glucose ambience can directly affect the UbA52
expression, MDCK cells were exposed to high glucose, and UbA52 mRNA
and protein expression was determined. The mRNA expression was
assessed by competitive RT-PCR. The quantitative RT-PCR analysis
revealed a linearity in the ratios of PCR products of wild type UbA52
cDNA to competitive plasmid DNA when plotted against
10 1-10 7 serial logarithmic dilutions of
the competitive plasmid DNA, as described previously (14). For
-actin control, a ratio of one was obtained at dilutions of
10 3-10 4 of the competitive plasmid DNA
(Fig. 5A). This ratio was
similar for cDNA prepared from MDCK cells exposed to 30 mM glucose (Fig. 5B), indicating no change in
the -actin mRNA expression in high glucose ambience. For UbA52
control (5 mM D-glucose or 30 mM
L-glucose), a ratio of 1 was obtained at dilutions of
10 4-10 5 of the competitive plasmid DNA
(Fig. 5C), although for cDNA prepared from MDCK cells
exposed to 30 mM glucose the ratio of 1 was obtained at
10 3-10 4 dilutions of the competitive DNA
(Fig. 5D), suggesting a 10-100-fold increase in the UbA52
mRNA population in high glucose ambience. Next, the UbA52 protein
expression was assessed in the MDCK whole cell lysate and ribosomal
fractions. Immunoprecipitation and Western blot analysis of the whole
cell lysate revealed a smear of ubiquitinated proteins ranging from
~25 to ~100 kDa. Also, a distinct band of ~16 kDa, corresponding
to the molecular mass of UbA52 protein, was observed (Fig.
5E). The intensity of the smeared band was increased to a
mild degree for the MDCK cells exposed to 30 mM compared
with the control. However, the intensity of the ~16-kDa band was
distinctly increased and was ~5-fold higher in cells exposed to high
glucose ambience compared with the control. Immunoprecipitation and
Western blot analyses of ribosomal fractions prepared from the MDCK
cells exposed to normal and high glucose ambience revealed similar
results, as observed with the whole lysate (Fig. 5F). The
intensity of ~16-kDa band in ribosomal fraction was ~10-fold higher
in MDCK exposed to 30 mM glucose compared with the
control.

View larger version (81K):
[in this window]
[in a new window]
|
Fig. 5.
Expression of UbA52 in MDCK cells cultured in
high glucose medium. A-D, competitive RT-PCR analysis
of -actin (A and B) and UbA52 (C
and D) in MDCK cells treated with 5 mM
D-glucose or 30 mM L-glucose
(B and D) and 30 mM
D-glucose (C and E). Serial
logarithmic dilutions of mutant competitive DNA template of UbA52 and
-actin were co-amplified with a fixed amount of first-strand
cDNA prepared from control and high glucose-treated MDCK cells. For
-actin, no significant differences in the amplification of the wild
type cDNA versus competitive plasmid DNA is observed
between the control and high glucose-treated cells (A
versus B), and the ratio of 1 is confined to the
10 3-10 4 log dilutions of the competitive
DNA. For UbA52, an increase in the amplification of wild type cDNA
versus competitive plasmid DNA is observed between control
and high glucose-treated cells (C versus D) when plotted
against the log dilutions of the competitive DNA, and the ratio of 1 shifted from 10 4-10 5 to
10 3-10 4. E, immunoprecipitation
and Western blot analyses showing a significant increase in the
expression of UbA52 (~16-kDa band indicated by arrow) in
the whole cell lysate of cells exposed to 30 mM of glucose.
Similarly, a mild increase is seen in the other ubiquitinylated
proteins that are represented in the smeared 25-100 kDa band.
F, immunoprecipitation and Western blot analysis of
ribosomal fraction of MDCK cells treated with 5 mM
(CONTROL) and 30 mM glucose, a major band of
~16 kDa is seen in ribosomal fraction, and its expression increased
when MDCK cells were exposed to 30 mM glucose.
|
|
Characterization of Mouse UbA52 Gene and Mapping of the
Transcription Initiation Site--
Using the PvuII mouse
DNA library provided in the GenomeWalker kit and PCR, a 1289-bp genomic
DNA product was obtained, and it contained a 891-bp stretch of
5'-untranslated region and a 384-bp segment of the translated region of
the UbA52 gene (Fig. 6A). The
5'-untranslated region had no homology with the human UbA52 gene.
Analysis of the 5'-untranslated promoter region of UbA52 revealed
several consensus sequences and binding sites including SP1, AP-1,
AP-2, TATA box, NF- B, GC box elements, glucose response-related E-box sequences (CAGCTG), and STREs (CCCCT). Another E-box with a palindromic consensus sequence (CAGGTA) with a 4 out 6 match was
present 6 nucleotides apart. The total stretch of 18 nucleotides included the E-boxes spanning from 117 to 134 bp. Other motifs included GATA-binding factor 2, heat shock factor,
CCAAT/enhancer-binding protein, Ras-responsive element-binding protein,
and Octamer factor-1 (Fig. 6A). Interestingly, by comparing
the cDNA and genomic DNA sequences of mouse UbA52, no introns were
found in the 5'-flanking region or within the coding segments of the
gene (Fig. 6A).

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 6.
Nucleotide sequence analyses of genomic DNA
of mice UbA52 gene. A, nucleotide sequence of the mouse
UbA52 genomic DNA. The base pairs downstream from the initiation ATG
codon of UbA52 are given as positive numbers. The base pairs upstream
of ATG codon are labeled as negative numbers. The mouse UbA52 cDNA
sequence is included as the second line under the genomic DNA sequence
starting from the 041 nucleotide extending into the
poly(A+) tail. The comparison of the cDNA and genomic
sequences indicates that there are no introns upstream or within the
coding region of the mouse UbA52 gene, which is in contrast to human
UbA52 gene. Further analysis of the 5'-untranslated region indicated
the presence of several motifs and response elements, which are
underlined. The important motifs include those of STRE
(CCCCT) and of the E-boxes (CAGCTG and CAGGTA). The two palindromic
E-boxes are spaced apart by 6 nucleotides and stretch from 117 to
134 bp. The STRE motif is located 18 bp upstream of the first E-box.
The TATA box (rectangular box) is present upstream of the
transcription site. Open reading frames (ORF(1) and
ORF(2)) are indicated by two angled arrows. The
termination codon is indicated by an octagon.
GATA-2, GATA-binding factor 2; HSF, heat shock
factor; C/EBP, CCAAT/enhancer-binding protein;
RREB-1, Ras-responsive element-binding protein;
Oct-1, Octamer factor-1. B, primary extension
analysis showing three transcription start sites
(arrowheads) similar to that of the human UbA52 gene. Among
the three extension products, the middle one of 62 bp yielded a
distinct band, and its nucleotide sequence (CGGCCG) is similar to that
indicated above (inset). C, the nucleotide
sequence of the putative transcription start site (CGGCCG) of mouse
UbA52 gene is similar that of the human. However, it is located 959
bp upstream from the initiation ATG codon in human. Also, the mouse
UbA52 lacked the 940-bp intronic segment upstream of the 5'-flanking
region.
|
|
Primer extension analysis revealed three extension products when
Ub-G1N(AS) primer and mouse total RNA or mRNA were used (Fig. 6B). No extension product was observed when tRNA was used.
The control RNA provided in the kit revealed an expected 87-bp primary extension reaction product. Among the three extension products, the
middle one of 62 bp yielded a distinct band, the analysis of which
revealed a major putative transcription start site with the CGGCCG
sequence (Fig. 6B, inset). It was located at 22
bp from the ATG initiation codon and 200 bp downstream of the TATA box (Fig. 6, A and C). The transcription start
site sequence (CGGCCG) of the mouse UbA52 gene was similar to that of
humans, but in the latter it was located 959 bp upstream from the
initiation ATG codon (Fig. 6C).
Promoter Activity Analysis--
To identify the minimal promoter
region that regulates the constitutive expression of the mouse UbA52
gene, a series of deletion constructs were generated and designated
DC1 891, DC2 741, DC3 592,
DC4 359, and DC5 198 (Fig.
7). The highest SEAP activity was
observed in DC5 198, which included sequences 198 bp of 5'-flanking region +68 bp from the initiation ATG codon. The activity was about ~32 times that of basic pSEAP vector with no insert. Because the highest basal promoter activity was confined in
DC5 198 bp that contains STRE and glucose
response-related E-box sequences, this construct was used to assay the
SEAP activity under different concentrations of glucose ranging from 0 to 30 mM. A dose-dependent increase in the SEAP
activity was observed (Fig. 8), and the
maximal activity was observed at 15 mM glucose concentration. The latter concentration was used for the mutational analysis of the UbA52 promoter.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 7.
Promoter analysis of mouse UbA52 gene.
Schematic representation of mouse SEAP activity of UbA52 promoter
(bar graphs) corresponding to reporter gene constructs with
sequential deletions are given on the left side of the
diagram. Five deletion constructs of pESAP2-enhancr/UbA52 promoter were
generated by PCR using sense and antisense primers. 48 h after
transfection with the constructs into COS7 cells, the media were
collected to measure the SEAP activity. The control included the
pSEAP2-basic vector, which contained neither SV40 enhancer nor
promoter. The highest enzyme activity of SEAP is seen in the
DC5 198 deletion construct, and it is ~32 times higher
than that of the pSEAP2-basic vector. The activity in this construct is
significantly higher than other deletion constructs. *,
p < 0.01. The data are presented as the means ± S.D. (n = 4).
|
|

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 8.
Effect of various concentrations of glucose
on the SEAP activity and mutation analysis of STRE and E-box. The
SEAP activities in COS7 cells transfected with DC5 198
plasmid are given as bar graphs with the means ± S.D.
(n = 4). The highest activity is seen at 15 mM glucose concentration in medium. The experiments were
performed in quadruplicate. The mutation in the STRE element
(CCCCT to CATsCT)
resulted in a substantial decrease in the SEAP activity. Similarly, the
MUT2 mutation in the E-box (CAGCTG
to TGGCTG) resulted in a significant decrease in
the SEAP activity. *, p < 0.01. However, the
MUT1 mutation in the E-box (CAGCTG
to CAGTTG) did not cause any significant change
in the SEAP activity. WT, wild type.
|
|
As indicated above, the DC5 198 deletion construct
included STRE (CCCCT) and glucose response-related E-box sequences
(CAGCTG); thus, mutations were created in these motifs (Fig. 8). The
mutant plasmids were transfected into COS7 cells, and the SEAP activity was determined under 5 and 15 mM glucose concentrations in
the medium. Mutation in the STRE motif (CCCCT to
CATCT) induced a remarkable decrease in the SEAP
activity at 15 mM glucose concentration compared with the
basal activity of the promoter. Mutation in the first E-box (MUT1,
CAGCTG to CAGTTG) did not
result any significant change in the SEAP activity compared with the
basal promoter activity. However another mutation in the first E-box
(MUT2, CAGCTG to TGGCTG)
resulted in a notable decrease in the SEAP activity (Fig. 8). These
findings suggest that both of these motifs are involved in the
up-regulation of UbA52 in high glucose ambience.
 |
DISCUSSION |
Diabetic nephropathy plays an important role in the development of
end stage renal disease. However, pathophysiologic mechanisms are still
incompletely understood. At the molecular level, several genes and
their functions in diabetic nephropathy have been characterized, whereas others remain to be discovered. So far, during the last decade,
various techniques that are modifications of the original method of
differential display have been used to identify the glucose-regulated
genes in different organ systems affected by diabetes mellitus. The
cells or organs investigated by the use of such modified methods
include retinal pericytes, aortic smooth muscle cells, cardiac
myocytes, and the kidney (8, 11, 16). Lately, to study the gene
regulation in diabetic nephropathy, we have successfully employed a
versatile technique, SSH-PCR, yielding <10% spurious signals, and a
number of differentially expressed genes have been identified. The
current study extends the exploration of the genes that are relevant to
diabetic nephropathy, and several genes exhibiting a transcriptional
response to hyperglycemia are described in this paper (Fig. 1). Some of
them (i.e. Rap1b, a small G-protein; RSOR, a renal specific
oxido-reductase; and Tim44, an inner mitochondrial membrane
translocase) have been described in our previous publications (11-13).
Interestingly, these genes and the other genes identified in this
study, like UbA52, are transcriptionally responsive to various forms of
stresses, including oxidant and carbonyl stresses. Both of these
stresses are relevant to the pathobiology of diabetic nephropathy and
apoptosis, as recently alluded to by Brownlee (17). The isolation of
genes responsive to a common transcriptional stimulus, i.e.
hyperglycemia, with the use of SSH-PCR underscores its utility in the
exploration of differential gene regulation. In this investigation, we
focus on the biology of the ubiquitin fusion protein UbA52 with regard to its relevance to diabetic nephropathy.
About 20 years ago, a protein that promoted the differentiation of
lymphocytes was isolated, and it is now known as ubiquitin (9). The
ubiquitin gene typically exists in two states. First, as a doublet,
e.g. ubiquitin B, or linear repeats in a polyubiquitin chain, i.e. ubiquitin C; second, the ubiquitin gene may be
fused to ribosomal proteins, i.e. UbA52 and UbA80 (9, 18,
19). Although ubiquitin has no intrinsic proteolytic activity, it plays an important role in the turnover of cellular proteins by closely regulating their degradation. The latter is a multistep
ATP-dependent pathway that involves the activation of
carboxyl terminus of ubiquitin, its conjugation with a specific
protein, and the addition of ubiquitins to form polyubiquitin, which is
then followed by degradation of ubiquitin-tagged protein in 26S
proteasome with the release of peptide fragments of the protein and
ubiquitin to be reutilized (9, 19). The ubiquitin-dependent
proteolysis is responsive to the stimuli of a diverse group of
molecules, including glucocorticoids and an inhibitor of NF- B, I B
(20), suggesting that the ubiquitin-dependent proteolytic
pathway is relevant in various pathobiological processes. The NF- B
has an important role in cachexia, the state with skeletal muscle loss,
and in support of the role of ubiquitin-proteasome pathway in muscle
wasting in diabetes is the seminal work of Mitch and co-workers
carried out during the last decade (10, 20, 21). These studies suggest
that metabolic acidosis and glucocorticoids are the major contributors
to ubiquitin-dependent muscle proteolysis in diabetes
mellitus along with the increased transcription of ubiquitin. This
catabolic state of muscle wasting seems to be the major phenotype in
diabetes mellitus, even when there may an abundance of anabolic growth
factors in circulation, like in this study where diabetic newborn mice
exhibited a substantial loss of body weight (0.58 ± 0.05 g versus 1.3 ± 0.07 g).
In addition to the skeletal muscle, an increased transcription of
ubiquitin in cardiac musculature has been reported in diabetes mellitus
(22). Moreover, it seems that there is a systemic increase in gene
transcription, because high blood levels of ubiquitin have been found,
and they have inverse correlation with the decrease in the muscle
action potential in diabetes mellitus (23). The above studies mainly
address the pathobiology of ubiquitin, whereas the current observations
describe the relevance of ubiquitin fusion protein, UbA52, in diabetes
mellitus. Moreover, the increased transcription of UbA52 in the kidneys
of diabetic mice and its renal mRNA expression rising
proportionally to blood glucose levels of newborn diabetic mice (Fig.
2) relate to an important organ-specific complication of diabetes
mellitus, i.e. diabetic nephropathy. Therefore, it should be
noted that in previous studies a ubiquitin-like protein, unrelated to
UbA52, was found to be differentially expressed in diabetic rats
with hyperglycemia (16).
Aside from the above studies, there is no report available in the
literature describing the distribution of UbA52 in the kidney. In the
present study, we could show by in situ hybridization and immunofluorescence techniques using an antibody generated against its
recombinant protein (Fig. 3) that in vivo expression of
UbA52 is confined to the renal tubules (Fig. 4). Moreover, its mRNA and protein expression is notably up-regulated in the tubular compartment of the kidneys of diabetic mice. In context of tubular expression of ubiquitin ligase (24), Nedd4, a protein with WW domain and ligase activity (25), and ubiquitin-conjugating enzyme E2
(26), selective expression of UbA52 in the renal tubules would suggest
that the ubiquitin-proteasome proteolytic system is indeed operative in
this compartment of the kidney and might play an important role in
diabetic nephropathy. To assess whether tubular cells are responsive to
high glucose ambience directly, MDCK cells, a tubular
epithelium-derived cell line, were employed. By RT-PCR analyses, a
10-100-fold increase in UbA52 mRNA expression was observed at 30 mM glucose in the culture medium (Fig. 5, A-D). In addition to the transcriptional effect on UbA52, increased translation reflected by the increased intensity of the ~16-kDa band
in the cell lysates was also noted (Fig. 5E). In addition, increased intensity of the smeared band was observed, which may be due
to the cross-reactivity of UbA52 antibody with other ubiquitinated proteins or polyubiquitin. Nevertheless, ~16-kDa band seems to correspond to the UbA52 ribosomal protein, because an identically sized
band with increased intensity was observed in the ribosomal fraction of
the glucose-treated MDCK cells (Fig. 5F). A similarly sized
band, corresponding to UbA52 protein, has been observed in the
ribosomal fractions prepared from various stages of development of
Drosophila melanogaster (27). The presence of the single ~16-kDa band in our studies is intriguing, because usually during the
proteolytic processing the co-synthesized ubiquitin is removed. It is
conceivable that this band represents a protein that underwent post-translational conjugation of carboxyl extension protein 52 to ubiquitin.
The next question that needs to be addressed is the mechanism by which
glucose increases the transcription of UbA52. It is known that
insulinopenia accompanied with acidosis contributes to cachexia (28),
although hyperinsulinemia and hyperaminoacidemia ameliorate the loss of
skeletal mass and decrease the transcription of ubiquitin (29),
indicating thereby that one needs to search for the promoter elements
of the gene that could regulate insulin signaling, such as E-box (30).
Another rationale to investigate the promoter analysis of UbA52 is
based on the studies indicating that insulinopenia and glucocorticoids
increase the transcription of ubiquitin C by involving Sp1 promoter
site (31). The mouse UbA52 promoter has some of the transcription
factors, such as Sp1, Ap1, and NF- B, which are similar to those in
the human homologue (32) and in ubiquitin C0 (33). Unlike the human
UbA52 promoter that shares features of many of the ribosomal genes, the
mouse UbA52 included canonical TATA box sequences and consensus
sequences for STRE, E-box, and heat shock factor elements (Fig.
6A). The transcription start site sequence (CGGCCG) was
similar, as assessed by primer extension analysis (Fig. 6B);
however, unlike in human UbA2, the mouse UbA52 had no introns
downstream of the transcription site (Fig. 6C).
Interestingly, no introns were found in the coding region of the UbA52
gene, indicating that the whole mouse gene is made up of a single exon,
unlike that of humans, which is made up of three exons (32). The mouse
cDNA sequences in the open reading frame revealed 85% homology
with human UbA52. Finally, the mouse UbA52 protein sequence was
identical to that of the human and also of the UbA80 up to the
60th amino acid residue (34).
For identification of the minimal promoter region, deletion constructs
of the 5'-flanking region of mouse UbA52 were prepared and transfected
into COS7 cells (a cell line derived from kidney cells), and SEAP
activity in the culture medium was determined (Fig. 7). Basal promoter
activity was confined to the +68 to 198 bp, i.e. in the
DC5 198 construct. This segment included STRE (CCCCT) and
two E-box (CAGCTG and CAGGTA) motifs that are known to be responsive to
glucose. Among these two palindromic E-boxes, the first one has a
perfect canonical CAGCTG sequence, whereas second one has an imperfect
consensus sequence with a match of 4 of 6 nucleotides. Relative to the
construct DC5 198, 75% of the SEAP activity could be
measured in the DC3 592 construct, which may be partly
attributed to the presence of additional STRE elements responsive to
carbonyl stress (Fig. 7). With the use of the DC5 198
construct, a dose-dependent increase in the SEAP activity
was observed (Fig. 8), and like the promoter activity of glucagon
receptor, the maximal activity was observed at a 15 mM
concentration of glucose (35). This is intriguing because the maximal
increase in the UbA52 mRNA expression is observed with 30 mM glucose in the mesangial cell
culture.2 These differences
may be attributed to a number of factors, including that the SEAP
activity was determined in COS7 cells and that the expression of
glucose transporters between these two cell lines may not be comparable.
The stretch spanning the two E-boxes is the major groove in the target
DNA, and it serves as the contact site for the interaction between
specific amino acids and the nucleotide bases. Such palindromic E-boxes
have been reported in promoters of other genes that are transcriptionally regulated by high glucose ambience. They include pyruvate kinase L, Spot14 (a lipogenesis-associated protein), and
glucagon receptor (35-37). They are expressed in the liver, the major
site for the transcription regulation of glucose. In pyruvate kinase L
and Spot14 gene, the E-box core motifs constitute the carbohydrate
response elements and are known as GIRE and ChoRE, respectively (36,
37). The location of glucose regulatory elements containing the E-box
motifs varies considerably among the three genes, e.g. from
144 to 168 nucleotides in pyruvate kinase L and from 1431 to
1448 nucleotides in Spot14, with an intermediate location for
the glucagon receptor, i.e. from 527 to 545 bp. In the
UbA52 the stretch of glucose regulatory elements containing E-boxes
seems to be confined between 117 and 134 bp (Fig.
6A).
The presence of STRE and E-boxes in the mouse UbA52 gene led us to
define their role in the transcriptional regulation of glucose. In the
glucagon receptor gene, the two E-boxes with CACGTG and CAGCTG
sequences are believed to be essential for promoter activity (35),
because a mutation in the CAGCTG motif to
CAGTTG results in a decrease in the activity of
the reporter gene. Similar observations were made for the UbA52 gene, where a mutation in CAGCTG motif to
TGGCTG resulted in a marked decrease in the
reporter gene activity at 15 mM glucose concentration,
suggesting a role for the E-box in the biology of UbA52 gene relevant
to diabetes mellitus (Fig. 8). However, no change in the reporter
activity was observed when mutation in the single base pair,
i.e. CAGCTG to
CAGTTG, was introduced. This may suggest that
mutation in two contiguous base pairs or alternatively the purine base
substitution is required to perturb the functions of E-box confined to
the major groves in the target DNA. In addition to the E-box,
mutational analyses were also carried for 18 bp upstream STRE (CCCCT)
motif. Ubiquitin mRNA expression is a major stress-induced
transcript in mammalian cells (38). Some of the physiologic and
pathologic stresses that increase its expression include exercise,
heat, ischemia, uncoupling of oxidative phosphorylation, alterations in
pH, calcium and glucose metabolism, and reactive oxygen species-induced
proteolysis (9, 10, 19). Given the fact that oxidant stress is believed to be a common denominator in the pathobiology of diabetes mellitus, the role of the STRE motif in the UbA52 reporter gene activity seemed
worth investigating. Like in manganese superoxide dismutase gene (39),
a mutation in CCCCT to
CATCT in at 15 mM glucose
concentration resulted in a marked suppression in UbA52 reporter gene
activity (Fig. 8), suggesting a role for the STRE motif in the
hyperglycemic state or in cells subjected to high glucose ambience.
In summary, the findings of this study indicate that the ubiquitin
fusion protein UbA52 is another important molecule relevant to the
pathobiology of diabetic nephropathy, and its transcription regulation
is modulated by the characteristic elements embedded in its promoter
region. It is anticipated that the observations made in this study give
an impetus to search for novel UbA52-interacting molecules, the biology
of which could further enhance our understanding of the pathogenesis of
diabetic nephropathy.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants DK-28492 and DK-60635.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of
Pathology, Northwestern University Medical School, 303 E. Chicago Ave., Chicago, IL 60611. Tel.: 312-503-0084; Fax: 312-503-0627;
E-mail: y-kanwar@northwestern.edu.
Published, JBC Papers in Press, May 24, 2002, DOI 10.1074/jbc.M204665200
2
L. Sun, X. Pan, J. Wada, C. S. Haas,
R. P. Wuthrich, F. R. Danesh, S. S. Chugh, and Y. S. Kanwar, unpublished results.
 |
ABBREVIATIONS |
The abbreviations used are:
SSH, subtraction
suppression hybridization;
MDCK, Madin-Darby canine kidney;
RT, reverse
transcription;
SEAP, secreted alkaline phosphatase promoter;
DC, deletion construct;
STRE, stress response element.
 |
REFERENCES |
| 1.
|
Price, R. G.,
and Hudson, B. G.
(1987)
Renal Basement Membranes in Health and Disease
, p. 439, Academic Press, Boston, MA
|
| 2.
|
Voziyan, P. A.,
Metz, T. O.,
Baynes, J. W.,
and Hudson, B. G.
(2002)
J. Biol. Chem.
277,
3397-3403[Abstract/Free Full Text]
|
| 3.
|
Feliers, D.,
Duraisamy, S.,
Faulkner, J. L.,
Duch, J.,
Lee, A. V.,
Abboud, H. E.,
Choudhury, G. G.,
and Kasinath, B. S.
(2001)
Kidney Int.
60,
495-504[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Gooch, J. L.,
Tang, Y.,
Ricono, J. M.,
and Abboud, H. E.
(2001)
J. Biol. Chem.
276,
42492-42500[Abstract/Free Full Text]
|
| 5.
|
Reddy, M. A.,
Thimmalapura, P. R.,
Lanting, L.,
Nadler, J. L.,
Fatima, S.,
and Natarajan, R.
(2002)
J. Biol. Chem.
277,
9920-9928[Abstract/Free Full Text]
|
| 6.
|
Natarajan, R.,
Gerrity, R. G., Gu, J. L.,
Lanting, L.,
Thomas, L.,
and Nadler, J. L.
(2002)
Diabetologia
45,
125-133[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Chen, S.,
Cohen, M. P.,
Lautenslager, G. T.,
Shearman, C. W.,
and Ziyadeh, F. N.
(2001)
Kidney Int.
59,
673-681[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Wada, J.,
Makino, H.,
and Kanwar, Y. S.
(2002)
Kidney Int.
61,
73-78[Medline]
[Order article via Infotrieve]
|
| 9.
|
Hershko, A.,
and Ciechanover, A.
(1998)
Annu. Rev. Biochem.
67,
425-479[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Mitch, W. E.,
and Goldberg, A. L.
(1996)
N. Engl. J. Med.
335,
1897-1905[Free Full Text]
|
| 11.
|
Sun, L.,
Chugh, S.,
Pan, X. M.,
Wallner, E. I.,
Wada, J.,
and Kanwar, Y. S.
(2001)
Kidney Int.
60,
2129-2141[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Yang, Q.,
Dixit, B.,
Wada, J.,
Tian, Y.,
Wallner, E. I.,
Srivastava, S. K.,
and Kanwar, Y. S.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
9896-9901[Abstract/Free Full Text]
|
| 13.
|
Wada, J.,
and Kanwar, Y. S.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
144-149[Abstract/Free Full Text]
|
| 14.
|
Kanwar, Y. S.,
Liu, Z. Z.,
Kumar, A.,
Usman, M. I.,
Wada, J.,
and Wallner, E. I.
(1996)
J. Clin. Invest.
98,
2478-2488[Medline]
[Order article via Infotrieve]
|
| 15.
|
Sherton, C. C.,
and Wool, I. G.
(1971)
Anal. Biochem.
41,
506-526
|
| 16.
|
Page, R.,
Morris, C.,
Williams, J.,
von Ruhland, C.,
and Malik, A. N.
(1997)
Biochem. Biophys. Res. Commun.
232,
49-53[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Brownlee, M.
(2001)
Nature
414,
813-820[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Sun, L.,
and Wuthrich, R. P.
(1999)
Biochem. Genet.
7,
139-147[CrossRef]
|
| 19.
|
Wilkinson, K. D.
(1995)
Annu. Rev. Nutr.
15,
161-189[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Du, J.,
Mitch, W. E.,
Wang, X.,
and Price, S. R.
(2000)
J. Biol. Chem.
275,
19661-19666[Abstract/Free Full Text]
|
| 21.
|
Price, S. R.,
Bailey, J. L.,
Wang, X.,
Jurkovitz, C.,
England, B. K.,
Ding, X.,
Phillips, L. S.,
and Mitch, W. E.
(1996)
J. Clin. Invest.
98,
1703-1708[Medline]
[Order article via Infotrieve]
|
| 22.
|
Liu, Z.,
Miers, W. R., We, L.,
and Barrett, E. J.
(2000)
Biochem. Biophys. Res. Commun.
276,
1255-1260[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Akarsu, E.,
Pirim, I.,
Capoglu, I.,
Deniz, O.,
Akcay, G.,
and Unuvar, N.
(2001)
Diabetes Care
24,
100-103[Abstract/Free Full Text]
|
| 24.
|
Sivaraman, L.,
Nawaz, Z.,
Medina, D.,
Conneely, O. M.,
and O'Malley, B. W.
(2000)
Breast Cancer Res. Treat.
62,
185-195[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Kamynina, E.,
Tauxe, C.,
and Staub, O.
(2001)
Am. J. Physiol.
281,
F469-F477[Abstract/Free Full Text]
|
| 26.
|
Wing, S. S.,
and Banville, D.
(1994)
Am. J. Physiol.
267,
E39-E48[Abstract/Free Full Text]
|
| 27.
|
Redman, K. L.
(1994)
Insect Biochem. Mol. Biol.
24,
191-201[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Mitch, W. E.,
Bailey, J. L.,
Wang, X.,
Jurkovitz, C.,
Newby, D.,
and Price, S. R.
(1999)
Am. J. Physiol.
276,
C1132-C1138[Abstract/Free Full Text]
|
| 29.
|
Larbaud, D.,
Debras, E.,
Taillandier, D.,
Samuels, S. E.,
Temparis, S.,
Champredon, G. J.,
and Attaix, D.
(1996)
Am. J. Physiol.
271,
E505-E512[Abstract/Free Full Text]
|
| 30.
|
Travers, M. T.,
Vallance, A. J.,
Gourlay, H. T.,
Gill, C. A.,
Klein, I.,
Bottema, C. B.,
and Barber, M. C.
(2001)
Biochem. J.
359,
273-284[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Marinovic, A. C.,
Mitch, W. E.,
and Price, S. R.
(2000)
J. Am. Soc. Nephrol.
11,
624 (abstr.)
|
| 32.
|
Baker, R. T.,
and Board, P. G.
(1991)
Nucleic Acids Res.
19,
1035-1040[Abstract/Free Full Text]
|
| 33.
|
Marinovic, A. C.,
Mitch, W. E.,
and Price, S. R.
(2000)
Biochem. Biophys. Res. Commun.
274,
537-541[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Kirschner, L. S.,
and Stratakis, C. A.
(2000)
Biochem. Biophys. Res. Commun.
270,
1106-1110[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Portois, L.,
Maget, B.,
Tastenoy, M.,
Perret, J.,
and Svoboda, M.
(1999)
J. Biol. Chem.
274,
8181-8190[Abstract/Free Full Text]
|
| 36.
|
Hasegawa, J.,
Osatomi, K., Wu, R. F.,
and Uyeda, K.
(1999)
J. Biol. Chem.
274,
1100-1107[Abstract/Free Full Text]
|
| 37.
|
Koo, S. H.,
and Towle, H. C.
(2000)
J. Biol. Chem.
275,
5200-5207[Abstract/Free Full Text]
|
| 38.
|
Fornace, A. J.,
Alamo, I.,
Hollander, M. C.,
and Lamoreaux, E.
(1989)
Nucleic Acids Res.
17,
1215-1230[Abstract/Free Full Text]
|
| 39.
|
Zahringer, H.,
Thevelein, J. M.,
and Nwaka, S.
(2000)
Mol. Microbiol.
35,
397-406[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. Dihazi, G. A. Muller, S. Lindner, M. Meyer, A. R. Asif, M. Oellerich, and F. Strutz
Characterization of Diabetic Nephropathy by Urinary Proteomic Analysis: Identification of a Processed Ubiquitin Form as a Differentially Excreted Protein in Diabetic Nephropathy Patients
Clin. Chem.,
September 1, 2007;
53(9):
1636 - 1645.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Nayak, P. Xie, S. Akagi, Q. Yang, L. Sun, J. Wada, A. Thakur, F. R. Danesh, S. S. Chugh, and Y. S. Kanwar
Modulation of renal-specific oxidoreductase/myo-inositol oxygenase by high-glucose ambience
PNAS,
December 13, 2005;
102(50):
17952 - 17957.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. G. Ewens, R. A. George, K. Sharma, F. N. Ziyadeh, and R. S. Spielman
Assessment of 115 Candidate Genes for Diabetic Nephropathy by Transmission/Disequilibrium Test
Diabetes,
November 1, 2005;
54(11):
3305 - 3318.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|